Identifying improvement opportunities in the management of hepatitis C;Identificación de oportunidades de mejora del tratamiento de la hepatitis C

Farmacia Hospitalaria

Volumn 30, Issue 3, 2006, Pages 154-160

  Márquez Peiró, Juan Francisco ^a,c   Perez Peiro C ^a   Carmena Carmena, J ^a   Jimenez Torres N V ^b  

^a HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c NONE   (United States)

Author keywords

Adverse effects; Hepatitis C; Improvement opportunities; Laser method; Peginterferon alfa; Pharmaceutical care

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ANEMIA; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; HEALTH CARE MANAGEMENT; HEPATITIS C; HUMAN; INFLUENZA; INFORMATION PROCESSING; INTERVIEW; MAJOR CLINICAL STUDY; METHODOLOGY; MORBIDITY; NEUTROPENIA; OUTPATIENT DEPARTMENT; PHARMACEUTICAL CARE; PUBLIC HEALTH; THROMBOCYTOPENIA;

EID: 33747679763     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(06)73966-6     Document Type: Article

References (22)

1. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26: 15S-20.
2. Kowdley KV. Interferon alfa for chronic hepatitis C: how do we define cure? Gastroenterology 1998; 115: 501.
3. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003; 52: 1784-7.
4. Sherman M, Bain V, Villeneuve JP, Myers RP, Cooper C, Martin S, et al. The management of chronic viral hepatitis: a Canadian consensus conference 2004. Can J Gastroenterol 2004; 18: 715-28.
5. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
6. a Edición. Hospital Universitario Dr. Peset. Valencia, 2005.
7. Nacional Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2003. (julio 2005). Disponible en: http: //ctep.cancer.gov/
8. Aspinall RJ, Pockros PJ. The management of side-effects during therapy for hepatitis. Aliment Pharmacol Ther 2004; 20: 917-29.
9. Cipolle RJ, Strand LM, Morley PC. Drug-related morbidity and mortality: the challenge for pharmaceutical care. Pharmaceutical Care Practice. New York: McGraw-Hill; 1998. p. 37-72.
10. Nomura H, Tanimoto H, Kajiwara E, Shimono J, Maruyama T, Yamashita N, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004; 19: 1312-7.
11. Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowsky MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302-11.
12. Dieterich DT, Wasserman R, Braun N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-Weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 2491-9.
13. Jacobson I, Brown R Jr, McCone J, Black M, Albert C, Dragustky M, et al. Weight based ribavirin dosing improves virologic response in HCV-infected genotype 1 African-Americans compared to flat dose ribavirin with peginterferon alfa-2b combination therapy. Hepatology 2004; 40: 217A.
14. Arase Y, Ikeda K, Suzuki F, Suzuki Y, Sayito S, Kobayashi M, et al. Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C. J Gastroenterol 2004; 39: 1090-4.
15. Pegasys® (peginterferon alfa-2a) solution for injection package insert. Nutley NJ. Roche Pharmaceuticals, December 2002.
16. Puoti M, Babudieri S, Rezza G, Viale P, Antonini MG, Maida I, et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antivir Ther 2004; 9: 627-30.
17. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
18. Peg-Intron® (peginterferon alfa-2b) powder for injection package insert. Kenilworth, NJ. Schering Corp. March 2003. Accessed online July 25, 2005, at: http: //www.spfiles.com/pipeg-intron.pdf
19. McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003; 7: 149-61.
20. Pockros PJ, Duchini A, McGuillan R, Nyberg LM, McHutchison J, Viernes E. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002; 97: 2040-5.
21. Curry MP, Afdhal RH. Use of growth factors with antiviral therapy for HCV. Clin Liver Dis 2005; 9: 439-51.
22. Carnicer F, Zapater P, Gutiérrez A, García A, Ruiz F, López M, en representación del grupo de estudio de la hepatitis C de Alicante. Treatment with pegylated interferon alpha-2b and ribavirin in patients unresponsive to previous treatments with standard interferon as monotherapy or combined with ribavirin. Rev Esp Enferm Dig 2005; 97: 306-16.